Deucravacitinib long-term efficacy through 4 years in Week 16 placebo crossover patients in the phase 3 POETYK PSO-1, PSO-2, and LTE program

Mark Lebwohl,1 Richard B. Warren,2,3 Shinichi Imafuku,4 Jerry Bagel,5 April W. Armstrong,6 Thierry Passeron,7 Subhashis Banerjee,8 Matthew J. Colombo,9 Thomas Scharnitz,10 Kim Hoyt,11 Diamant Thaqi,12 Andrew Blauvelt13

1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK; 3University Hospital of Nice, Nice, France; 4Bristol Myers Squibb, Princeton, NJ, USA; 5Psoriasis Treatment Center of Mark Lebwohl,1 Richard B. Warren,2,3 Shinichi Imafuku,4 Jerry Bagel,5 April W. Armstrong,6 Thierry Passeron,7 Subhashis Banerjee,8 Matthew J. Colombo,9 Thomas Scharnitz,10 Kim Hoyt,11 Diamant Thaqi,12 Andrew Blauvelt13

Objective

- To report the long-term clinical efficacy of deucravacitinib in patients who crossed over from placebo to deucravacitinib at Week 16 in POETYK PSO-1 and subsequently enrolled in the LTE trial.

Methods

- Study design: In POETYK PSO-1 and PSO-2 trials, adult patients with moderate to severe plaque psoriasis were randomized 1:1 to deucravacitinib or placebo. In POETYK LTE, adult patients with moderate to severe plaque psoriasis who completed the 24-week LTE maintenance treatment were enrolled in the LTE trial.

\[ \text{Study population:} \]

- Patients were randomized to deucravacitinib or placebo at baseline and crossed over to deucravacitinib at Week 16 in POETYK PSO-1, continued treatment through Week 52, and crossed over to the LTE trial.

\[ \text{Outcome:} \]

- Efficacy was assessed in patients with up to 192 weeks of deucravacitinib exposure (following 16 weeks of placebo) at Week 208 of the LTE trial. PASI 75, 90, 99, TFR, and sPGA were evaluated.

\[ \text{Statistical analysis:} \]

- Efficacy was analyzed through the POETYK LTE trial cutoff date of November 1, 2023.

Results

- Efficacy analyses were performed using an ad-hoc analysis, where data were used to evaluate long-term efficacy, in addition to other analyses.

Table 1: Baseline patient demographics and disease characteristics

\[ \text{Table 1: Baseline patient demographics and disease characteristics} \]

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo (n = 298)</th>
<th>Deucravacitinib (n = 298)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>49.8 (11.2)</td>
<td>49.9 (10.9)</td>
<td>0.82</td>
</tr>
<tr>
<td>Sex, male, %</td>
<td>53.6</td>
<td>51.9</td>
<td>0.52</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>81.9 (16.2)</td>
<td>82.1 (15.6)</td>
<td>0.70</td>
</tr>
<tr>
<td>PASI score, mean (SD)</td>
<td>21.1 (7.9)</td>
<td>21.0 (8.4)</td>
<td>0.76</td>
</tr>
</tbody>
</table>

Figure 1: Mechanism of action of deucravacitinib

Figure 2: Study design and analysis population

<table>
<thead>
<tr>
<th>Study</th>
<th>POETYK PSO-1</th>
<th>POETYK PSO-2</th>
<th>POETYK LTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>n = 168</td>
<td>n = 511</td>
<td>n = 298</td>
</tr>
<tr>
<td>Deucravacitinib</td>
<td>n = 168</td>
<td>n = 511</td>
<td>n = 298</td>
</tr>
</tbody>
</table>

Conclusions

- Deucravacitinib provides long-term efficacy in patients with moderate to severe plaque psoriasis who are candidates for systemic therapy through 4 years of treatment, with no new safety signals observed.

References


Acknowledgments

- The authors would like to thank the patients, the 24-week POETYK PSO-1 trial investigators, and the POETYK LTE trial investigators for their contributions.

Disclosures

- The authors report no competing interests associated with the current study.

Presented at the Fall Clinical Dermatology Conference for PA and NP, May 31, June 1, 2023, Nashville, TN.

Email: marklebow@gmail.com

This paper may not be reproduced without prior permission from the authors.